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Glucose Metabolism in Cancer-Associated Fibroblasts 
 
ABSTRACT 
Under normal conditions, non-transformed cells rely on glycolysis followed by 
oxidative phosphorylation to generate ATPs. When oxygen is scarce or when cells are 
actively proliferating, cellular ATPs come mainly from glycolysis. Pyruvate is converted into 
lactate to allow glycolysis to continue. Interestingly, cancer cells have adapted to favor 
lactate production even at normal oxygen tensions, exhibiting a metabolic shift known as 
the Warburg effect. However, the metabolic state of other cellular constituents within the 
tumor remains mostly unknown.  
Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells. They aid 
tumor growth and metastasis by providing growth factors, cytokine, ECM remodeling 
proteins and interacting with other tumor stromal cells. Here I show that the Warburg effect 
also operates in stromal fibroblasts of the tumor microenvironment. Using mass 
spectrometry, genetic mouse models, gene expression and methylation studies, I 
demonstrate that CAFs from human and mouse mammary tumors exhibit hyperactive 
glycolysis and a metabolic shift towards lactate production. Furthermore, this phenotype 
may be sustained through epigenetic modifications of endogenous hypoxia-inducible factor 
1α, key regulatory enzymes fructose-bisphosphatase 1 and pyruvate kinase M2. Depletion 
of stromal fibroblasts or suppression of lactate production specifically in these cells alters 
the metabolic profile of not only the tumors but also the cancer cells and results in impeded 
tumor growth.  
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These results collectively suggest that tumor growth is dependent on metabolic state 
and metabolic support of stromal fibroblasts, highlighting these cells as attractive 
therapeutic targets in controlling cancer progression. 
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
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Breast cancer incidence, development, diagnosis and treatment 
Breast cancer has been one of the most prevalent cancers and one of the leading 
cancer killers of women worldwide (World Health Organization, 2009), especially in North 
America region (Figure 1). 1 in 8 U.S. women develops invasive breast cancer and there 
are ~230,000 new diagnosis with ~40,000 expected death in 2013 (Centers for Disease 
Control and Prevention, 2011; Susan G. Komen for the Cure, 2012). Although rare, ~2,200 
expected diagnosis and ~400 deaths are expected for men in 2013 (Susan G. Komen for 
the Cure, 2012; Breastcancer.org, 2012). Since the development of mammography, more 
cases of breast cancer have been diagnosed at earlier stages where they can be 
successfully treated. During the 1980s and 1990s, incidence rate of early-stage breast 
cancer increased greatly and has remained stable while diagnosis of metastatic stage has 
dropped slightly (Susan G. Komen for the Cure, 2012). Between 1999 and 2005, total 
breast cancer incidence in U.S. women decreased by 2% per year due to the reduced 
usage of hormone replacement therapy (Breastcancer.org, 2012). However, breast cancer 
mortality rate has continued to increase for African American women (Susan G. Komen for 
the Cure, 2012).  
Breast cancer develops in three major stages, from normal tissue to ductal 
carcinoma in situ to invasive ductal carcinoma and ends with metastatic disease (Polyak 
and Kalluri, 2010). The normal female breast structure includes the ductal epithelium and 
the myoepithelial cells surrounded by the basement membrane and separated from the 
connective tissue made up of fibroblasts, capillaries and extracellular matrix (Figure 2A). At 
early stage of cancer development, proliferation of transformed epithelial cells fills the 
lumen, forming ductal carcinoma in situ (DCIS). Other features of dysplastic lesion include 
increased number of blood vessels, dense extracellular matrix (ECM) and increased 
number of associating fibroblasts (Figure 2B). As breast cancer progresses, epithelial 
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cancer cells break free from the confinement of the basement membrane, forming areas 
with duct-like appearance, hence named invasive ductal carcinoma (IDC). Stromal 
environment contains many newly formed blood vessels, inflammatory factors and 
myofibroblasts (Figure 2C). In advanced stage, nearby tissue is affected with the invasion of 
cancer cells, evolving into metastatic disease (Figure 2D). Besides DCIS and IDC, other 
types of breast cancers include invasive lobular carcinoma, medullary carcinoma, mucinous 
(colloid) carcinoma, papillary carcinoma, tubular carcinoma, and inflammatory breast cancer 
(Susan G. Komen for the Cure, 2012).  
 
 
Figure 1. Women breast cancer incidence in the world with North America as one of the 
leading regions. Data from Forouzanfar et al. (2011). 
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Figure 2. Stages of breast cancer development in human. (A) The normal female breast 
structure with organized ductal epithelium, myoepithelial cells, basement membrane, and 
connective tissue of fibroblasts, capillaries and extracellular matrix. (B) Proliferation of 
transformed epithelial cells in ductal carcinoma in situ (DCIS). (C) Invasive ductal carcinoma 
and (D) advanced invasive ductal carcinoma. Image is reproduced from Kalluri and 
Zeisberg (2006). 
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Breast cancer is usually first detected through physical examination or routine 
screening. Diagnosis can only be made through biopsy of the lump or abnormal area guided 
by appropriate imaging technologies – x-ray, ultrasound or MRI. Next, the biopsied tissue 
undergoes pathological evaluation. Staging of the diagnosis depends on the size and the 
location of the tumor, the number of affected lymph node, and whether metastasis has 
occurred. In general, there are 4 stages of breast cancers; DCIS at stage 0 and metastatic 
breast cancer at stage IV. Patients diagnosed with early stage breast cancer also undergo 
tests to predict metastasis probability, which is determined by lymph node and estrogen 
receptor status.  
Women with familial history of breast cancer and/or have taken hormone 
replacement therapy are at higher risk for developing the disease. To choose appropriate 
treatment approach, molecular characteristics of the tumor are important. These include 
estrogen and progesterone receptor status, HER2/neu (ErbB2) status, and proliferation 
rate. Hormone receptor-positive breast cancers are often treated with hormone therapies, 
including Tamoxifen and aromatase inhibitors such as Anastrozole, Ietrozole or 
Exemestane (Susan G. Komen for the Cure, 2012). The principle is to prevent cancer cells 
from receiving the estrogen needed for tumor growth, either by lowering the estrogen level 
or by inhibiting the receptor. Hormone receptor-positive tumors have a lower chance of 5-
year recurrence than negative tumors. HER2/neu-positive tumors represent about 15-20% 
of all breast cancers (Susan G. Komen for the Cure, 2012). For these tumors, treatment 
with the antibody Trastuzumab is effective (trade name: Herceptin). Monitoring of treatment 
often uses positron emission tomography (PET). PET scan utilizes radioactive glucose, 
which accumulates in extremely metabolic cells, a distinct characteristic of cancer cells.  
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Normal glucose metabolism versus the Warburg effect 
In the past few years, cancer biology research has increasingly been attracted to 
metabolism and energy production in cancer cells. Under normal conditions, non-
transformed cells rely on glucose for energy. Glycolysis pathway converts glucose into 
pyruvate, yielding 2 mol of ATP per mol of glucose (Figure 3A). Pyruvate is further shuttled 
through the tricarboxyclic acid cycle (TCA, also known as Krebs or citric acid cycle) inside 
the mitochondria (Lehninger et al., 2004) (Figure 3B). This process is coupled with oxidative 
phosphorylation and the electron transport chain to produce an additional 34 mol of ATP 
(Lehninger et al., 2004) (Figure 3B). Such high output of energy can only be possible in the 
presence of normal oxygen level. When oxygen is scarce or when cells are proliferating, 
glycolysis becomes the sole energy source. Lactate dehydrogenase converts pyruvate into 
lactate to regenerate NAD+ necessary for glycolysis to continue (Figure 4). Although this 
mode of energy production is far less productive than the TCA cycle and oxidative 
phosphorylation, it takes less time to generate ATPs. Moreover, intermediate metabolites 
from glycolysis can be used to produce nucleotides through the pentose phosphate 
pathway and to synthesize amino acids (Lehninger et al., 2004).  
Interestingly, cancer cells prefer glycolysis coupled with lactate production even in 
abundance of oxygen (Figure 4). This phenomenon, named aerobic glycolysis or the 
Warburg Effect, was discovered by Dr. Otto Warburg while he observed cancer cells 
growing in vitro (Warburg et al., 1930). Unlike normal differentiated cells, cancer cells 
exhibit high glucose intake and high glycolysis rate. Substantial research over the past 80 
years has revealed that one of the reasons cancer cells adopt aerobic glycolysis is due to 
oncogenes and tumor suppressors (Table 1). Many oncogenes including PI3K, c-Myc and 
Ras regulate glucose transport, glycolysis and TCA (Fritz and Fajas, 2010; Vander Heiden 
et al., 2009) while tumor suppressor p53 regulates the pentose phosphate pathway and 
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oxidative phosphorylation (Jones and Thompson, 2009). In addition, mutations in β-F1-
ATPase and D-loop mitochondrial DNA, which likely impair oxidative phosphorylation, have 
been linked to poor prognosis in breast cancer (Isidoro et al., 2005; Tseng et al., 2006).  
 
 
    
 
Figure 3. Diagrams showing glucose metabolism and energy production in normal, 
differentiated cells. (A) Glycolysis metabolizes glucose into pyruvate. (B) Pyruvate is 
shuttled through the TCA cycle, followed by oxidative phosphorylation and electron 
transport chain to produce ATPs. Images are reproduced from Biochem.co (2010). 
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Figure 4. Glucose metabolism and energy production in normal versus tumor tissue. 
Differentiated tissues use glycolysis coupled with oxidative phosphorylation for high ATP 
output in normal oxygen. During hypoxia, lactate is produced following glycolysis to 
regenerate NAD+ necessary for continuing glycolysis. Proliferative tissue and cancer cells 
adapt to this alternative mode of metabolism even in normal oxygen. Image is reproduced 
from Vander Heiden et al. (2009). 
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Table 1. Table of oncogenes and tumor suppressors known to regulate metabolic pathways. 
Information from Fritz and Fajas (2010), Vander Heiden et al. (2009), Jones and Thompson 
(2009), and Shackelford and Shaw (2009).  
 
 
 
Some of the molecular metabolic consequences of oncogenes and tumor 
suppressors have been explored. Unlike differentiated cells, cancer cells increase glucose 
uptake by upregulating glucose transporter such as GLUT1 (Seyfried and Shelton, 2010; 
Vander Heiden et al., 2009; Koukourakis et al., 2006). Hexokinase (HK), which converts 
glucose into glucose-6-phosphate in the first step of glycolysis, is also highly upregulated 
(Seyfried and Shelton, 2010; Vander Heiden et al., 2009). Moreover, HK2 in particular is 
found to be expressed primarily in cancer cells (Seyfried and Shelton, 2010). The last step 
in glycolysis is pyruvate synthesis by pyruvate kinase (PK). Recently, Christoff et al. (2008) 
discovered that cancer cells switch from using pyruvate kinase isoform m1 (PKM1) to 
isoform m2 (PKM2) to efficiently shift their metabolism toward aerobic glycolysis (Christoff 
et al., 2008). Pyruvate, the resulting product, is metabolized into lactate by lactate 
dehydrogenase A (LDHA) and subsequently shuttled out of the cells through lactate 
exporter MCT4 (Seyfried and Shelton, 2010; Koukourakis et al., 2006). Extracellular lactate 
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can be taken back into the cells through lactate importer MCT1. However, MCT1 is usually 
downregulated, allowing the cancer cells to discard the accumulating intracellular lactic acid 
(Seyfried and Shelton, 2010; Koukourakis et al., 2006). Lactate dehydrogenase B (LDHB) 
which catalyzes the synthesis of pyruvate from lactate (Lehninger et al., 2004), is active in 
the normal liver but its expression and function in cancer cells remain unknown. Another 
important player is pyruvate dehydrogenase kinase (PDK). PDK resides inside the 
mitochondria and functions to prevent the entry of pyruvate into the TCA cycle by inhibiting 
pyruvate dehydrogenase (PDH) (Lehninger et al., 2004). In cancer cells, PDK1 and PDK4 
are most often upregulated (Seyfried and Shelton, 2010). By upregulating key glycolysis 
enzymes and TCA cycle negative regulator, cancer cells are able to adopt aerobic 
glycolysis as their main mode of metabolism and energy production. A summary of the key 
enzymes involved in the Warburg effect is presented in Figure 5.  
Pathways involved in glucose metabolism have been explored as potential targets 
for cancer therapy. Metabolic inhibitors such as dichloroacetic acid (DCA), 3-bromopyruvate 
acid (3BP) and 2-deoxy-d-glucose have been investigated clinically and seem to be 
promising anti-cancer agents (Seyfried and Shelton, 2010; Fulda et al., 2010). 3BP inhibits 
HK2 and DCA inhibits PDK while 2-deoxy-d-glucose prevents the uptake of functional 
glucose. Other potential targeting compounds include HK2 peptide and LDHA shRNA 
(Fulda et al., 2010).  
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Figure 5. Altered glucose metabolism in cancer cells. Affected metabolic enzymes and 
transporters including GLUT1, HK2, PKM2, LDHA, PDK, MCT4 and MCT1 are shown in 
bolded letters. Information from Seyfried and Shelton (2010), Vander Heiden et al. (2009), 
Koukourakis et al. (2006), and Christoff et al. (2008). 
  
Stromal fibroblasts in cancer 
Fibroblasts are known to be special cells with spindle-like, mesenchymal 
appearance. Their role as regulators of ECM synthesis, structure and replacement in the 
connective tissues makes them the responsible cell type in the wound healing process. 
Fibroblasts are also found in excess in diseased settings such as organ fibrosis and 
cancers. Furthermore, fibroblasts of the same or different origins exhibit substantial 
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heterogeneity. To identify them, researchers rely on many protein markers such as 
vimentin, α-smooth-muscle-actin (αSMA), desmin, fibroblast-activation protein, and 
fibroblast-specific-protein 1 (Skalli et al., 1989; Schmitt-Graff et al., 1994; Sugimoto et al., 
2006; Kalluri and Zeisberg, 2006). Expression of different combinations of these markers in 
fibroblasts has been observed in various pathological conditions. This characteristic pattern 
is believed to reflect the adaptation of fibroblasts to their environment.  
A prominent subclass of fibroblast is the myofibroblast. These cells not only behave 
like fibroblasts, but also have contractility like smooth muscle cells (Gabbiani, 1992). Like 
smooth muscle cells, they express αSMA, which has become their distinct identification 
marker. Although the exact origin of myofibroblasts is controversial, it is now generally 
accepted that myofibroblasts can come from various sources. These include resident 
fibroblasts, bone marrow-derived progenitors and epithelial or endothelial cells. Resident 
fibroblasts are thought to expand and transdifferentiate into myofibroblasts while bone 
marrow-derived progenitors are recruited to the site prior to transdifferentiation. Recent 
emerging evidences suggest that myofibroblasts can come from mesenchymal transition of 
epithelial or endothelial cells (Hinz et al., 2007; Zeisberg et al., 2007). While normally rare, 
myofibroblasts are abundant in tumors, especially in high-grade malignancies and are 
associated with poor prognosis (Surowiak et al., 2007; Yamashita et al., 2012; Yazhou et 
al., 2004). Myofibroblast activation is thought to be unrestrained in the growing tumor, unlike 
the carefully regulated wound healing process in which they normally function. Due to this 
lasting response by the myofibroblasts, cancer is considered by many as a wound that 
never heals.  
In breast cancer, stroma constitutes over 80% of the tumor mass (Dvorak, 1986). 
αSMA+ myofibroblasts in tumors, also known as cancer-associated fibroblasts (CAFs), are 
the most prominent among the stromal cells. Research over many years have implicated 
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CAFs in tumorigenesis, tumor growth and progression. Although still controversial, there are 
some evidences suggesting the role of CAFs in tumor initiation. CAFs can stimulate tumor 
formation when co-injected subcutaneously with non-tumorigenic breast cancer cells lines in 
immunodeficient mice (Olumi et al., 1999). Additionally, neoplastic transformation is 
observed in epithelial cells from normal breast following overexpression of transforming 
growth factor β (TGFβ) or hepatocyte growth factor (HGF) in myofibroblasts (Kuperwasser 
et al., 2004).  
 CAFs are known to aid tumor growth and metastasis by providing growth factors 
and ECM remodeling proteins. They supply HGF and epithelial growth factor (EGF) which 
stimulate cell proliferation and promote resistance against apoptosis (Kalluri & Zeisberg, 
2006). Many laboratories have shown that CAFs, not normal fibroblasts, substantially 
enhance tumor growth when co-injected with cancer cells (Orimo et al., 2001; Olumi et al., 
1999; Kuperwasser et al., 2004). CAFs-derived matrix metalloproteinases (MMP), such as 
MMP-1, MMP-3, MMP-7 and MMP-11, degrade ECM and basement membrane, a crucial 
step in transitioning from carcinoma in situ to invasive carcinoma (Bisson et al., 2003; Hu 
and Polyak, 2008; MacDougall and Matrisian, 1995).  
CAFs also play important roles in building blood vessels in the tumor. Pro-
angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth 
factor 2 (FGF-2) and platelet-derived growth factors (PDGFs) are secreted by CAFs, 
mediating angiogenesis (Crawford et al., 2009; Dong et al., 2004; Hlatky et al., 1994; Fang 
et al., 2001). Increased tumor angiogenesis is observed in cancer xenografts co-injected 
with CAFs (Tuxhorn et al., 2002; Orimo et al., 2001). More importantly, myofibroblast-
derived VEGF can compensate for the loss of VEGF in cancer cells (Dong et al., 2004).  
CAFs express many pro-inflammatory cytokines and chemokines, recruiting immune 
cells to the tumor site as a result (Silzle et al., 2003; Allinen et al., 2004). By interacting and 
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facilitating communication among different cells in the tumors, these multitaskers mediate a 
permissive environment favorable for cancer cells in growth and progression. Figure 6 
summarizes the numerous roles of CAFs in the tumor.  
Given how active and different CAFs are compared to normal fibroblasts, it is 
expected that CAFs sustain genetic mutations. Patocs et al. (2007) noted TP53 mutations in 
fibroblasts associated with sporadic breast carcinoma. However, following studies by Qiu et 
al. (2008), Campbell et al. (2008) and Hosein et al. (2010) all dispute this claim. Instead, 
there are evidences suggesting epigenetic changes. By analyzing global DNA methylation 
profiles using methylation-specific digital karyotyping, Hu et al. (2005) has identified altered 
DNA methylation patterns not only in tumor epithelial cells but also stromal fibroblasts. 
Another study testing for the presence of methylation in breast carcinoma CAFs has 
described particular DNA methylation of selected genes (Fiegl et al., 2006). In addition, 
stromal myofibroblasts isolated from human gastric cancers display global DNA 
hypomethylation (Jiang et al., 2008). 
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Figure 6. The multifunction of cancer-associated fibroblasts in the tumor. Image is 
reproduced from Kalluri and Zeisberg (2006). 
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Glucose metabolism in cancer-associated fibroblasts 
Despite their major presence and contributing role in tumor progression, the 
metabolic state of CAFs remains unclear. The tumor environment contains an abundance of 
growth factors such as TGFβ, PDGF and FGF2 which can induce fibroblast proliferation 
(Polyak et al., 2010; Skobe et al., 1998; Bissell et al., 2001). Many have reported that CAFs 
are more proliferative than their normal counterparts in vitro and exist in much larger 
numbers in breast tumors versus adjacent normal tissues (Hawsawi et al., 2008; 
Rozenchan et al., 2009; Mercier et al., 2008; Shimoda et al., 2009). As described earlier in 
this chapter, proliferating cells display a different metabolic pattern than non-proliferating 
cells. In addition, the tumor microenvironment lacks oxygen and nutrients (Harris, 2002; 
Brown and Wilson, 2004; Pouysségur et al., 2006; Kallinowski et al., 1989; Vaupel et al., 
1987). Hypoxia-induced factor 1α is known to transcriptionally induce expressions of 
GLUT1, HK2, PKM2, PDK1, LDHA and phosphofructokinase (PFK) in many cell lines 
including mouse embryonic fibroblasts (Semenza et al., 1994; Semenza et al., 1996; Ebert 
et al., 1995; Firth et al., 1995; Iyer et al., 1998; Yeung et al., 2008; Kim et al., 2006; 
Papandresu et al., 2006). The metabolic state of CAFs may be affected by such tumor 
microenvironment.  
Our understanding of glucose metabolism in CAFs is limited. Koukourakis et al. 
(2006) examine colorectal adenocarcinoma tissues and show high expressions of MCT1 
and LDHA, and low expression of GLUT1 in CAFs. For breast carcinoma, some interesting 
clues come from the research group of Michael Lisanti. In Caveolin-1 deficient murine bone 
marrow cells (which express myofibroblast-associated proteins), glycolysis enzymes such 
as GLUTs, PKM2, PGKL, LDHA, ALDOA, ENO1, TI1 and PGM1 are reportedly upregulated 
(Pavlides et al., 2009). hTERT-immortalized fibroblasts transformed with oncogenic H-Ras 
(G12V) display enhanced glycolysis and decreased protein expressions of oxidative 
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phosphorylation complexes II and V (Migneco et al., 2010). Knock down of mitochondrial 
transcription factor A (TFAM) in these cells shows loss of respiratory chain components, 
increased hydrogen peroxide and lactate, and promotes tumor growth in a xenograft model 
with MDA-MB-231 breast cancer cells (Balliet et al., 2011). In addition, MCT4 is expressed 
in normal fibroblasts upon exposure to MCF7 breast cancer cells (Whitaker-Menezes et al., 
2011). Lisanti’s group proposes a reverse Warburg effect model. In this model, CAFs 
(defined as Caveolin-1 knockout cells) are the cells that experience aerobic glycolysis in the 
tumor and CAFs-derived lactate and pyruvate are used by cancer cells to perform oxidative 
phosphorylation (Pavlides et al., 2009). Albeit interesting, the experimental approaches 
employed by the group contain serious caveats. Whether Caveolin-1 negative is a good 
marker for myofibroblasts is questionable. Caveolin-1, located at the cell membrane, plays a 
role in endocytosis and signal transduction (Razani et al., 2001; Couet et al. 1997; Lajoie 
and Nabi, 2010). Its knockout may change fundamental functions in cells such as 
metabolism. Oncogenic Ras and hTERT control important biological functions of cell 
proliferation and senescence respectively. Fibroblasts transformed with these genes are 
likely to behave differently.  
Similar to other functions described earlier, glucose metabolism in CAFs may 
support tumor growth. A clear understanding of their metabolic role inside the tumors may 
provide new gateways to applicable therapies. In this dissertation, I first determine the 
metabolic differences between CAFs and normal fibroblasts, then explore the potential 
mechanisms which mediate such metabolic changes, and lastly examine the metabolic role 
of these cells in tumor growth. 
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CHAPTER 2 
 
METABOLIC PROFILE OF CANCER-ASSOCIATED FIBROBLASTS 
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Work collaboration and contribution 
 The presented work involved indispensable collaborations. Human normal mammary 
fibroblasts and cancer-associated fibroblasts were grown from breast biopsies obtained as 
part of an institutionally approved clinical study in collaboration with Dr. Sughra Raza 
(Brigham and Women’s Hospital, Boston). Metabolomics was done through collaboration 
with Dr. John Asara (BIDMC, Boston). Mitochondrial function tests were carried out in 
collaboration with Dr. Marcia Haigis (Harvard Medical School, Boston). 
 In addition, a number of individuals contributed to the work. In particular, I formulated 
the hypotheses and determined the experimental approach and direction together with my 
dissertation advisor Dr. Raghu Kalluri. αSMA-RFP mouse strain was generated by Dr. 
Yingqi Teng and Dr. Joyce O’Connell (BIDMC and Harvard Medical School, Boston). Dr. 
Sylvia Vong and Dr. Joyce O’Connell assisted with human fibroblast culture (BIDMC and 
Harvard Medical School, Boston). Dr. Joyce O’Connell also provided technical help with 
cancer cell implantation, RNA preparation for microarray and mtDNA content measurement. 
In addition, microarray data analysis, heat map generation and metabolomics data analysis 
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Introduction 
The tumor environment contains an abundance of growth factors such as TGFβ, 
PDGF and FGF2 which can induce fibroblast proliferation. Many have reported that 
fibroblasts are more proliferative and exist in much larger number in tumors than adjacent 
normal tissues (Skobe and Fusenig, 1998; Bissell and Radisky, 2001; Polyak and Kalluri, 
2010). The tumor environment also lacks oxygen and nutrients due to the speedy growth of 
cancer cells (Harris, 2002; Brown and Wilson, 2004; Pouysségur et al., 2006; Kallinowski et 
al., 1989; Vaupel et al., 1987). The metabolic state of CAFs may be affected by such tumor 
microenvironment.   
Our understanding of glucose metabolism in CAFs is limited. Koukourakis et al. 
(2006) examine colorectal adenocarcinoma tissues and show high expressions of MCT1 
and LDHA, and low expression of GLUT1 in CAFs. For breast carcinoma, some interesting 
clues come from the research group of Michael Lisanti. In Caveolin-1 deficient murine bone 
marrow cells (which express myofibroblast-associated proteins), glycolysis enzymes such 
as GLUTs, PKM2, PGKL, LDHA, ALDOA, ENO1, TI1 and PGM1 are reportedly upregulated 
(Pavlides et al., 2009). hTERT-immortalized fibroblasts transformed with oncogenic H-Ras 
(G12V) display enhanced glycolysis and decreased protein expressions of oxidative 
phosphorylation complexes II and V (Migneco et al., 2010). Knock down of mitochondrial 
transcription factor A (TFAM) in these cells shows loss of respiratory chain components, 
increased hydrogen peroxide and lactate, and promotes tumor growth in a xenograft model 
with MDA-MB-231 breast cancer cells (Balliet et al., 2011). In addition, MCT4 is expressed 
in normal fibroblasts upon exposure to MCF7 breast cancer cells (Whitaker-Menezes et al., 
2011). Lisanti’s group proposes a reverse Warburg effect model. In this model, CAFs 
(defined as Caveolin-1 knockout cells) are the cells that experience aerobic glycolysis in the 
tumor and CAFs-derived lactate and pyruvate are used by cancer cells to perform oxidative 
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phosphorylation (Pavlides et al., 2009). Albeit interesting, the experimental approaches 
employed by the group contain serious caveats. Whether Caveolin-1 negative is a good 
marker for myofibroblasts is questionable. Caveolin-1, located at the cell membrane, plays a 
role in endocytosis and signal transduction (Razani et al., 2001; Couet et al. 1997; Lajoie 
and Nabi, 2010). Its knockout may change fundamental functions in cells such as 
metabolism. Oncogenic Ras and hTERT control important biological functions of cell 
proliferation and senescence respectively. Fibroblasts transformed with these genes are 
likely to behave differently. A direct comparison of unaltered endogenous CAFs and their 
normal counterparts is preferable.  
In this chapter, we take a dual approach, utilizing unaltered human-derived 
fibroblasts and αSMA+ fibroblasts isolated from mouse to understand the baseline metabolic 
differences between CAFs and normal fibroblasts. This information is the foundation for our 
mechanistic and functional studies.  
 
Experiments and results 
To determine whether CAFs exhibit altered metabolism, fibroblasts were directly 
isolated from normal mammary tissue and invasive ductal carcinoma of breast cancer 
patients and grown under aerobic conditions (37
o
C, 5% CO2, 20% O2). We subjected these 
cells to a microarray analysis to identify potential differences in gene expression between 
CAFs (hCAFs) and normal (hNMFs). Pathway analyses of the data pointed to a differential 
gene expression profile in glycolysis, mitochondrial functions and oxidative phosphorylation 
(Figure 7A). Further assessment of the expression patterns demonstrated a trend for 
increased expression of genes involved in glycolysis. Transcriptional expression of key 
glycolysis genes Glut1, Hk2, Pfkl, Pkm2, Ldha, and lactate exporter Mct4 by quantitative 
RT-PCR found that almost all of them were upregulated in hCAFs compared to NMFs 
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(Figure 7B). The amount of secreted lactate was significantly greater in hCAFs (Figure 7C), 
which was consistent with the increase Mct4 expression (Figure 7B). 
 
 
 
Figure 7. Comparison of metabolic gene expressions between CAFs and NMFs from 
human. (A) Microarray analysis of gene expressions in glycolysis, mitochondrial functions 
and oxidative phosphorylation pathways as defined by Ingenuity Pathway Analysis 
software. Heat maps represent gene expression of hCAF in comparison to hNMF, green 
indicates less and red indicates more detected mRNA. (B) Detection of important glycolysis 
enzymes and lactate exporter MCT4 by quantitative RT-PCR. (C) Relative concentration of 
lactate in the culture medium. Data are represented as mean  SEM; *p<0.05. 
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Although hCAFs had increased glycolysis gene expressions, they might not have 
real functional effects. Thus, we performed targeted mass spectrometry to assess 
metabolite accumulations in both fibroblast groups.  Metabolomic analyses revealed 
contrasting metabolite accumulations between hCAFs and hNMFs. In particular, hCAFs 
produced greater amounts of metabolites in glycolysis, mitochondrial functions, and 
oxidative phosphorylation (Figure 8A, 8B, and 8C, respectively).  Interestingly, assays for 
oxygen consumption rate (OCR) and proton production rate (PPR) showed an increase 
trend in hCAFs compared to hNMFs (Figure 8E) without any difference in mitochondrial 
DNA content (Figure 8D). However, activities of the electron transport chain complexes 
hCAFs were ambiguous. Complex I seemed to be increased; complex IV seemed to be 
unchanging; and complex III seemed to be decreased (Figure 8F).  
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Figure 8. Comparisons of metabolites and mitochondrial functions between CAFs and 
NMFs from human. hNMFs and hCAFs were subjected to metabolomics studies. Relative 
abundance of each metabolite between hCAFs and hNMFs was calculated for glycolysis 
(A), mitochondrial functions (B) and oxidative phosphorylation (C) pathways as defined by 
Ingenuity Pathway Analysis software.  (D) Relative mitochondrial DNA content between 
hCAFs and hNMFs. (E) Mitochondrial oxidative respiration activities in hCAFs compared to 
hNMFs: oxygen consumption rate (OCR, unit in pmoles/min/OD, p=0.25) and proton 
production rate (PPR, unit in pmoles/min/OD, p=0.11). (F) Electron transport chain 
complexes I, II and IV (p=0.44, p=0.56 and p=0.65 respectively). Data are represented as 
mean  SEM; *p<0.05. 
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Figure 8 (continued) 
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Another differential mitochondrial function between hCAFs and hNMFs is antioxidant 
activity. Cellular activities such as oxidative phosphorylation create various reactive oxygen 
species (ROS) as byproducts. Known ROS are superoxide anion, peroxide, hydrogen 
peroxide, hydroxyl radical and hydroxyl ion. One of the most important endogenous 
antioxidants against ROS, glutathione (GSH), functions by donating its reducing 
equivalents, becoming oxidized into glutathione disulfide (GSSG) in the process. 
Glutathione reductase (GR) keeps the system balanced by reducing GSSG back to GSH, 
allowing antioxidant activity to continue (Figure 9A). Human CAFs displayed a significantly 
higher ratio of GSSG to GSH with significantly less expression of GR than NMFs (Figure 9C 
and 9B, respectively). This data indicates defective antioxidant activity in CAFs. 
For comparative studies, murine stromal fibroblasts from normal mammary tissue 
and mammary tumors were isolated from a transgenic mouse model in which the αSMA 
promoter drives the expression of red fluorescent protein (RFP). Isolated mouse fibroblasts 
were grown in aerobic condition (37
o
C, 5% CO2, 20% O2) and then subjected to microarray, 
quantification of glycolysis gene expression and targeted mass spectrometry. Similar to 
human fibroblasts, pathway analyses of microarray pointed to a differential gene expression 
profile in glycolysis (Figure 10A). Glut1, Hk2, Pfkl, Pkm2, and Ldha were also upregulated in 
mCAFs compared to mNMFs (Figure 10B). Furthermore, metabolomic analyses uncovered 
that mCAFs likewise produce greater amounts of metabolites in glycolysis, mitochondrial 
functions, and oxidative phosphorylation (Figure 10C, 10D, and 10E, respectively).   
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Figure 9. Decreased GR in hCAFs. (A) Schematic summarizing function of GR. Briefly, 
endogenous antioxidant GSH guarding against cellular ROS becomes oxidized into GSSG. 
GR converts GSSG back into GSH, allowing GSH to continue its antioxidant function. (B) 
GSSG and GSH in hNMFs and hCAFs were measured in metabolomic studies. Ratio of 
GSSG to GSH was computed for each group and graphed. (C) hCAFs contains significantly 
less Gr mRNA than hNMFs as detected by quantitative real time PCR. Data are 
represented as mean  SEM; *p<0.05. 
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Figure 10. Comparison of metabolic profile between CAFs and NMFs from mouse. (A) 
Microarray analyses of gene expressions in glycolysis, mitochondrial functions and 
oxidative phosphorylation pathways as defined by Ingenuity Pathway Analysis software. 
Heat maps represent gene expression of mCAFs in comparison to mNMFs, green indicates 
less and red indicates more detected mRNA. (B) Detection of important glycolysis enzymes 
and lactate transporter by quantitative RT-PCR. mNMFs and mCAFs were also subjected to 
metabolomic studies. Relative abundance of each metabolite between hCAFs and hNMFs 
was calculated for glycolysis (C), mitochondrial functions (D) and oxidative phosphorylation 
pathways (E) as defined by Ingenuity Pathway Analysis software.  Data are represented as 
mean  SEM; *p<0.05. 
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Figure 10 (continued) 
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Discussion 
 Our different experimental approaches comparing breast CAFs to their normal 
counterparts from human and mouse support the hypothesis that stromal fibroblasts of the 
tumor microenvironment exhibit the Warburg effect. Their metabolic phenotype is defined as 
enhanced glycolysis activities and lactate production under aerobic conditions. In addition, 
CAFs seem to have increased oxygen consumption with defective antioxidant activity.   
 Our finding of ambiguous oxidative phosphorylation in CAFs surprisingly contradicts 
findings previously reported by the research group of Michael Lisanti. The observation 
made by the group that CAFs exhibit decreased mitochondrial oxidative phosphorylation 
may be specific to the Caveolin-1 knockout cell population. In addition, immortalized 
fibroblast cell lines that were transformed with oncogenic activated Ras were used in the 
experiments. Oncogenic Ras has been shown to not only alter glucose metabolism but also 
affect mitochondrial functions in mouse fibroblasts (Chiaradonna et al., 2006). In general, 
RAS controls a major signal transduction pathway that promotes cell growth and 
proliferation, consequentially affecting metabolism of the cells. These are possible 
explanations for the difference in our findings. 
 However, our examination of oxidative phosphorylation is not extensive. Activities of 
other electron transport chain complexes need to be assessed in order to obtain a complete 
picture of the entire pathway. It is possible that increase in cellular ROS (due to defective 
antioxidant activity and increase in oxygen consumption) may negatively affect the function 
of the protein complexes in the electron transport chain. Thus, the slowed pathway 
accumulates intermediate metabolites as a consequence.  
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CHAPTER 3 
 
MECHANISMS OF METABOLIC ALTERATIONS IN  
CANCER-ASSOCIATED FIBROBLASTS 
 
33 
 
Work collaboration and contribution 
The presented work involved indispensable collaborations. Human normal mammary 
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the hypotheses and determined the experimental approach and direction together with my 
dissertation advisor Dr. Raghu Kalluri. Dr. Joyce O’Connell provided critical experimental 
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Introduction 
Stromal cells isolated from normal and tumor tissue are known to maintain their 
differences even after prolonged cell culture and in xenograft studies (Bissell and Radisky, 
2001; Tlsty and Hein, 2001; Orimo et al., 2005). The dramatic changes in gene expression 
patterns but lack of clonally selected somatic mutations in CAFs suggest potential 
epigenetic alterations (Qiu et al., 2008; Campbell et al., 2008; Hu and Polyak, 2008; Hosein 
et al., 2010). Indeed, by analyzing global DNA methylation profiles using methylation-
specific digital karyotyping Hu et al. (2005) have identified altered DNA methylation patterns 
not only in the tumor epithelial cells but also in stromal fibroblasts. Another study testing for 
the presence of methylation in breast carcinoma CAFs has described particular DNA 
methylation of selected genes (Fiegl et al., 2006). In addition, stromal myofibroblasts 
isolated from human gastric cancers display global DNA hypomethylation (Jiang et al., 
2008). Epigenetic changes in CAFs may explain the differential metabolic pattern reported 
in Chapter 2 of this dissertation.  
Another potential mechanism for metabolic alterations in CAFs is hypoxia. The tumor 
environment lacks oxygen due to the fast growth speed of cancer cells. Hypoxia affects 
many cellular responses including the switch from oxidative phosphorylation to anaerobic 
glycolysis in normal cells. Most of glycolysis enzymes are transcriptional targets of HIF1α 
such as GLUT1, HK2, PFK, PKM2 and LDHA (Semenza et al., 1994; Semenza et al., 1996; 
Ebert et al., 1995; Firth et al., 1995; Iyer et al., 1998; Yeung et al., 2008). In multiple cell 
lines including cancer cells and mouse embryonic fibroblasts, PDK1 is a direct target of 
HIF1α, inhibiting pyruvate conversion into acetyl CoA at the beginning of TCA cycle (Kim et 
al., 2006; Papandresu et al., 2006). HIF1α has been established as a key player in the 
reprograming of metabolism in cancer cells and is being investigated as clinical therapy 
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(Semenza, 2010). With all its close connection to glucose metabolism, tumor hypoxia may 
be the trigger of Warburg effect in CAFs with HIF1α as a mediator.  
 
Experiments and results 
Epigenetic mechanism 
To assess epigenetic changes in CAFs, we performed whole genome methylation 
array on the fibroblasts isolated and cultured from human breast biopsies. The high 
resolution array surveyed ~27,500 CpG islands utilizing close to 490,000 probes. Compared 
to hNMFs, hCAFs showed impressive contrasting differential patterns of methylation (Figure 
11).  
 
 
Figure 11. Whole genome methylation array comparing CAFs to NMFs. High resolution 
methylation array was performed to survey ~27,500 CpG islands on different hCAFs and 
hNMFs. Representative heat map shows impressive contrasting methylation patterns 
between CAFs and NMFs; unmethylated genes are shown in green and methylated genes 
are shown in red.  
36 
 
For glycolysis, 35 genes were significantly different at various DNA sites (Table 2). 
Gene methylation can occur at upstream of transcription start site, 5’UTR, 1st exon, gene 
body and even 3’URT regions at rare occasion. In epigenetic studies, only ~10% of 
methylation is usually correlated with gene expression for most regions. The 5’URT region, 
which often contains many gene expression elements, has up to 80% chance of 
correspondence to expression. Among the glycolysis genes which were differentially 
methylated in hCAFs compared to hNMFs, 6 genes had detected probes located in the 
5’UTR region – Fbp1, AldoB, Dhrs9, Aldh1B1, Pkm2 and LdhB. Between these genes, 
Fbp1 and Pkm2 attracted attention, being not only the rate limiting steps but also key 
regulatory enzymes of glycolysis. PKM2 (pyruvate kinase m2 isoform) regulates the 
synthesis of pyruvate from phosphoenolpyruvate, functioning as positive regulator of 
glycolysis. In contrast, FBP1 functions as a negative regulator of glycolysis, converting 
fructose-1,6 bisphosphate back to fructose-6-phosphate.  
 
Table 2. Glycolysis genes differential methylated in CAFs. Data was extracted from whole 
genome methylation array. Table shows the gene region where differential methylation was 
detected including body, TSS200, TSS1500, 1
st
 exon, 5’UTR and 3’UTR. Only genes with 
p-value of <0.05 are listed. ∆ Methylation is the difference between hCAFs and hNMFs, 
shown as a percentage. For each gene, a positive numbers indicates a higher methylation 
and a negative number indicates lower methylation in hCAFs. 
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Table 2 (continued)  
 
Genes Region of Methylation ∆ Methylation P-Value 
ACSL1 Body -19.00% 0.0349 
ACSS1 TSS200 2.60% 0.0233 
ACCSS2 Body;TSS1500 -15.00% 0.0168 
ADH1B TSS1500 -11.30% 0.0313 
ADH6 TSS1500 -9.50% 0.0271 
ADHFE1 Body -8.60% 0.0297 
ADHFE1 Body 3.30% 0.0054 
ALDH1A3 Body 0.80% 0.0394 
FBP1 5'UTR 0.80% 0.0412 
ALDH1L1 Body -7.90% 0.0451 
ALDH3A2 Body -5.50% 0.0457 
ALDH3A2 Body 2.10% 0.0114 
ALDH3B1 TSS1500 -6.20% 0.0422 
ALDH3B1 Body -10.20% 0.0074 
ALDH3B1 TSS200 -9.50% 0.008 
ALDH3B1 1stExon;5'UTR -12.80% 0.0185 
ALDH7A1 TSS200 1.70% 0.0414 
ALDOA TSS200;TSS1500;5'UTR 2.70% 0.0032 
ALDOB TSS1500 -12.40% 0.0079 
ALDOB 5'UTR -9.60% 0.0219 
DHRS9 5'UTR;5'UTR -6.00% 0.0384 
DHRS9 TSS1500;5'UTR -9.00% 0.0184 
ENO3 TSS1500 3.80% 0.0436 
ALDH1B1 5'UTR -4.70% 0.0392 
G6PC3 TSS1500 -9.50% 0.0257 
G6PC3 TSS200 -0.40% 0.0346 
GALM TSS200 -4.80% 0.0434 
GCK Body -14.40% 0.007 
HK1 Body 9.40% 0.0379 
HSD17B10 TSS200;TSS200 -9.00% 0.0289 
LDHA 1stExon;5'UTR -1.00% 0.0112 
LDHAL6B 1stExon;Body -3.80% 0.0446 
PKM2 5'UTR -13% 0.0138 
PDHA1 1stExon; 5’UTR -7.90% 0.0355 
PFKFB1 TSS1500 -10.90% 0.0432 
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Table 2 (continued) 
Genes Region of Methylation ∆ Methylation P-Value 
PFKFB1 TSS1500 -7.60% 0.026 
PFKFB3 Body -8.60% 0.002 
PFKFB3 Body -1.90% 0.0431 
PFKFB3 TSS200 -0.50% 0.047 
PFKFB3 TSS200 -0.20% 0.0274 
PFKFB3 TSS1500 7.40% 0.0026 
PFKFB3 Body 2.10% 0.0172 
PFKFB3 Body 5.30% 0.0089 
PFKFB4 TSS1500 -0.70% 0.0443 
PFKP Body 3.00% 0.0468 
PFKP Body 3.70% 0.0422 
PGAM2 TSS1500 14.90% 0.0145 
PGK1 1stExon;5'UTR -7.10% 0.0392 
PGK2 TSS200 -6.50% 0.027 
PGM5 3'UTR -11.00% 0.0076 
PGM5 Body -6.60% 0.005 
PKLR TSS200;Body -6.00% 0.0497 
PKLR TSS200;Body -5.50% 0.0419 
LDHB 5'UTR -0.70% 0.0448 
RDH14 TSS1500 1.30% 0.0461 
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In the case of Pkm2, hCAFs exhibited less methylation compared to hNMFs in the 
array with a difference of -13%, making it the 4
th
 most differentially methylated gene 
detected in glycolysis. This hypomethylation was confirmed by methylated DNA 
immunoprecipitation (Figure 12A and B). In addition, Pkm2 mRNA expression was 
significantly less in hNMF #33 which had the highest amount of methylated DNA; this 
suppression was attenuated by treatment with 5-aza-2’-deoxycytidine, an inhibitor of DNA 
methyltransferase (Figure 12C). 
In the case of Fbp1, although the difference of methylation in the array was minimal, 
Fbp1 was confirmed to be hypermethylated in hCAFs in two different validation methods, 
bisulfite sequencing of its promoter region (Figure 13A) and methylated DNA 
immunoprecipitation (Figure 13B and C). Furthermore, hypermethylation of Fbp1 in hCAFs 
correlated with its decreased mRNA level which was rescued with the treatment of 5-aza-2’-
deoxycytidine (Figure 13D). 
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Figure 12. Hypomethylation of Pkm2 in CAFs. Decreased methylation of Pkm2 in hCAFs 
was detected by methylated DNA immunoprecipitation (MeDIP). Methylated DNAs were 
precipitated with 5-methyl-cytidine antibody from purified genomic DNAs and subjected to 
specific PCR. PCR gel image is shown in (A) and quantification of %DIP/input DNA is 
shown in (B). (C) shows the relative mRNA of Pkm2 as measured by quantitative real time 
PCR in hNMF #33, hCAFs and hNMF #33 treated with 5-aza-2’-deoxycytidine (AZA). Data 
are represented as mean  SEM; *p<0.05. 
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Figure 13. Hypermethylation of Fbp1 in CAFs. (A) Bisulfite sequencing of 21 CpG islands in 
the promoter region. The methylation array included probes covering from the 6
th
 island to 
the 9
th
 island. Each square represents an individual sequenced clone. A filled square 
indicates methylation; an emptied square indicates unmethylation. Increased methylation of 
Fbp1 in hCAFs was also confirmed with Methylated DNA Immunoprecipitation (MeDIP). 
Methylated DNAs were precipitated with 5-methyl-cytidine antibody from purified genomic 
DNAs and subjected to specific PCR. PCR gel image is shown in (B) and the quantification 
of %DIP/input DNA is shown in (C). (D) Relative mRNA of Fbp1 as measured by 
quantitative real time PCR in hNMFs, hCAFs and hCAFs treated with 5-aza-2’-
deoxycytidine (AZA). Data are represented as mean  SEM; *p<0.05. 
42 
 
Figure 13 (continued) 
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Figure 13 (continued) 
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Hypoxia mechanism 
First, to determine whether hypoxia can modulate expression of glycolysis enzymes in 
human breast fibroblasts, normal fibroblast cell line #21 was cultured in hypoxia (3% O2) 
alternating with normal oxygen level (20% O2) for 8 days and gene expressions were 
assessed with quantitative real time PCR. Glut1, Hk2, Pfkl, Pkm2 and LdhA were affected 
with increased mRNA expressions coincided mostly with hypoxia (Figure 14A). As these 
glycolysis enzymes are transcriptional targets of HIF1α (Yeung et al. 2008) and our 
methylation array has indicated less methylation of Hif1α in hCAFs compared to hNMFs 
(mean difference 1.4%, p=0.015), methylation status of Hif1α in hNMFs exposed to hypoxia 
was assessed by methylated DNA immunoprecipitation. In 3 different hNMF cell lines #27, 
#32, and #54, Hif1α was sufficiently hypomethylated after 120 hours of chronic hypoxia 
(Figure 14B). Interestingly, this change was maintained despite reoxygenation for the next 24 
hours (Figure 14B), suggesting that chronic hypoxia induced hypomethylation of Hif1α in 
fibroblasts.  
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Figure 14. Hypoxia effect on expression of glycolysis genes and Hif1α methylation in NMFs. 
(A) hNMF #21 was subjected to hypoxia alternating with normal oxygen culture condition for 8 
days and expressions of glycolysis genes Glut1, Hk2, Pfkl, Pkm2 and LdhA were assessed 
by quantitative RT-PCR. The average of all 5 genes for each time point was also calculated 
and graphed. Hypoxia modulates expressions of all 5 genes. (B) 3 different hNMF cell lines, 
#27, #32 and #54 were subjected to hypoxia for 120 hours then reoxygenated for 24 hours 
and their Hif1α methylation status were assessed with methylated DNA immunoprecipitation. 
Methylated DNAs were precipitated with 5-methyl-cytidine antibody from purified genomic 
DNAs and subjected to PCR with Hif1α specific primers. Chronic hypoxia for 120 hours 
results in sustained decreased methylation of Hif1α. Data are represented as mean  SEM; 
*p<0.05. 
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If hypoxia in fact induces permanent hypomethylation of Hif1α, Hif1α mRNA level 
should remain elevated in spite of longer reoxygenation. To test this hypothesis, hNMFs #32 
and #54 were exposed to hypoxia for different durations of 24, 72, 120, and 168 hours each 
followed with reoxygenation for 48 hours. Cells were collected at different time points for 
assessment of mRNA and proteins to compare Hif1α expressions. Longer reoxygenation was 
designed deliberately to determine whether increased Hif1α mRNA and protein would still be 
maintained. As expected, hypoxia induced a significant increase of Hif1α mRNA and protein 
compared to baseline level (0hr) in both tested cell lines (Figure 15A and B). More 
importantly, the mRNA continued to increase in reoxygenation post hypoxia and this increase 
was only observed after 120 hours of hypoxia but not at earlier time points (Figure 15A). 
HIF1α protein accumulated in hypoxia and remained relatively unchanged after 
reoxygenation (Figure 15B and C). These results strongly suggest that prolonged hypoxia can 
induce stable and likely permanent expression of Hif1α mRNA and protein in fibroblasts. 
In the context of a tumor, fibroblasts exposed to chronic hypoxia undergo Hif1α 
hypomethylation, leading to stable and prolonged gene expression and consequently 
inducing its transcriptional targets including glycolysis enzymes. According to this 
mechanism, Hif1α in hCAFs should be less methylated and its mRNA and protein should be 
higher in hCAFs than in hNMFs. In fact, none of the hCAFs tested showed methylation PCR 
band while all of the hNMFs did (Figure 16A). Quantification of the band intensities confirmed 
significant hypomethylation in hCAFs (Figure 16B). In addition, detected mRNA was ~1.7 fold 
higher in hCAFs (Figure 16C). Although Hif1α protein levels varied between different cell lines 
(Figure 16D), hCAFs showed more HIF1α when normalized by loading control (Figure 16E). 
These data suggest that Hif1α can be a contributing factor to the enhanced glycolysis in 
CAFs we observed in chapter 2 of this dissertation.  
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Figure 15. Chronic hypoxia induces stable expression of Hif1α. hNMFs #32 and #54 were 
subjected to hypoxia for different durations (24, 72, 120, and 168 hours) followed by 
reoxygenation for 48 hours. (A) Hif1α mRNA was assessed with quantitative RT-PCR. 
Graphs represent fold difference relative to baseline of 0hr. Hif1α at baseline is significantly 
less compared to all conditioned samples. (B) Western blots comparing hypoxia and 
reoxygenation samples detected 3 bands of molecular weights 100-120KDa. All band 
intensities were quantified with NIH ImageJ software and average HIF1α/ACTIN ratios were 
calculated for comparison (C). Significant increase in HIF1α protein in all samples is observed 
when compared to baseline but no difference between hypoxia and reoxygenation samples is 
detected. Data are represented as mean  SEM; *p<0.05. 
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Figure 15 (continued) 
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Figure 16. Methylation status and expression of Hif1α in CAFs versus NMFs. (A) 
Comparison of Hif1α methylation between hNMFs and hCAFs by methylated DNA 
immunoprecipitation. Methylated DNAs were precipitated with 5-methyl-cytidine antibody 
from purified genomic DNAs and subjected to PCR with Hif1α specific primers. PCR gel 
image (A) and quantification of %DIP/input DNA (B) show hypomethylated Hif1α in hCAFs. 
(C) Hif1α mRNA expression is more in hCAFs compared to hNMFs per quantitative RT-
PCR assessment. (D) HIF1α protein levels were assessed with Western blot. Intensities of 
all 3 bands of 100-120KDa were quantified with NIH ImageJ software and average 
Hif1α/Tubulin ratios were calculated for comparison (E). hCAFs exhibit ~2 fold more HIF1α 
protein than hNMFs. Data are represented as mean  SEM; *p<0.05. 
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Figure 16 (continued) 
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Discussion 
 In this chapter, our experiments explore and support two mechanisms of Warburg 
effect in CAFs. Firstly, enhanced glycolysis may be due to hypermethylation of negative 
regulators such as Fbp1 and hypomethylation of positive regulator such as Pkm2. 
Secondly, chronic hypoxia can manipulate glycolysis gene expressions via inducing 
hypomethylation of Hif1α. Investigation reveals that hNMFs lost methylation of Hif1α when 
deprived of oxygen for as little as 4 to 5 days. Reoxygenation up to 48 hours does not 
reverse this loss. Moreover, sustained Hif1α methylation change upon chronic hypoxia 
correlates with its increased mRNA and protein expressions.  
 Our data demonstrate an upregulation of Pkm2 in stromal fibroblasts of the tumor 
microenvironment. Pkm2 expression in cancer cells has been previously implicated in the 
regulation of tumor metabolism (Christofk et al., 2008) and its inhibitors are being 
researched. If the 4T1 cancer cell line used in our study does not express Pkm2, the 
designed drugs will likely target tumor-promoting stromal fibroblasts in Pkm2 negative 
cancers. Whether this will be effective therapy is worth exploring.  
The studies presented here suggest that tumor hypoxia, a driver for expression of 
glycolysis and lactate production genes (Denko, 2008; Semenza, 2010), likely influences 
stromal fibroblasts along with cancer cells. Similar to muscle cells in the body, fibroblasts 
experiencing oxygen starvation exhibit increased production and removal of cellular lactate. 
Another possible explanation is that cancer cells directly induce metabolic changes in their 
tumor constituents. Whether cancer cells induce metabolic changes in fibroblasts 
independent of general tumor oxidative stress deserves a separate investigation. 
Our studies also discover that stromal fibroblasts undergo epigenetic alterations that 
possibly contribute to their sustained Warburg phenotype in the context of a growing tumor. 
Besides Fbp1 and Pkm2, other metabolic genes in CAFs may have undergone similar 
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epigenetic modifications. Most methylation studies of metabolic genes in cancer have 
focused on cancer cell lines of the corresponding carcinoma, suggesting that 
hypermethylation or hypomethylation of important metabolic genes take place in the cancer 
cells (Wolf et al., 2011; Goel et al., 2003; Xu et al., 2012). Our results provide the first 
evidence that similar epigenetic modifications also exist in cancer-associated fibroblasts. 
Tumor hypoxia is again a likely contributing factor, having been shown to induce loss of 
global methylation in normal human dermal fibroblasts (Shahrzad et al., 2007).  
More importantly, we uncover a direct involvement of tumor hypoxia in regulating 
metabolic reprogramming in stromal fibroblasts - hypomethylation of Hif1α. Speculations in 
the field have favored epigenetic alterations as an explanation for the vast differences 
between CAFs and normal fibroblasts. Our experiments identify cancer cell-induced hypoxia 
as the potential initiator of a chain of epigenetic modifications, and ultimately, also 
responsible for changing the metabolic profile of neighboring stromal fibroblasts to favor 
tumor growth. These results demonstrate the need for more attention to hypoxic regions in 
tissues during cancer screening, and suggest the avoidance of hypoxia as a potential 
method for cancer prevention.  
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CHAPTER 4 
 
FUNCTIONAL CONTRIBUTION OF METABOLIC ACTIVITIES  
IN STROMAL FIBROBLASTS TO TUMOR GROWTH 
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Work collaboration and contribution 
The presented work involved indispensable collaboration. Metabolomics was done 
through collaboration with Dr. John Asara (BIDMC, Boston).  
In addition, a number of individuals contributed to the work. In particular, I formulated 
the hypotheses and determined the experimental approach and direction together with my 
dissertation advisor Dr. Raghu Kalluri. αSMA-tk mouse strain was generated by Dr. Yingqi 
Teng and Dr. Joyce O’Connell (BIDMC and Harvard Medical School, Boston). Cancer cell 
implantation, tumor measurements and immunostaining for αSMA-tk treated with GCV were 
performed by Dr. Joyce O’Connell (BIDMC and Harvard Medical School, Boston). She also 
helped with metabolomics data analysis and heat map generation. Technical help with Pdk 
knockdown and PCR confirmation came from Dr. Valerie LeBleu (BIDMC and Harvard 
Medical School). I performed all remaining experiments.  
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Introduction 
CAFs have been shown to provide growth factors such as TGFβ, cytokines such as 
IL-1 and ECM remodeling proteins such as MMPs to aid tumor growth and metastasis 
(Kalluri and Zeisberg, 2006). The metabolic status of CAFs may play a role in aiding tumor 
metabolism. Supporting evidence includes significant inhibition of tumor growth by 2-deoxy-
D-glucose and DCA in xenograft model of MDA-MB-231mammary epithelial cancer cells co-
injected with Cavelin-1 knockout fibroblasts (Bonuccelli et al., 2010). Indeed, Pavlides et al. 
(2009) have hypothesized that the Warburg effect in CAFs provides adjacent cancer cells 
with energy-rich metabolites such as lactate and pyruvate. In a xenograft mouse model 
using MDA-MB-231, synthetic glycolysis fibroblasts overproduce lactate and promote tumor 
growth independent of angiogenesis (Balliet et al., 2011). In addition, oncogenic Ras-
transformed fibroblasts exhibiting Warburg phenotype enhance tumor growth of MDA-MB-
231 (Migneco et al., 2010). Decreased tumor growth has been observed in a lung mouse 
model and xenograft human colorectal cancer following treatments with a small molecule 
inhibitor of MCT1 (Sonveaux et al., 2008). However, there is no direct evidence to address 
the role of glucose metabolism inside CAFs in tumor growth.   
In this chapter, we first assess the functional contribution of αSMA+ myofibroblasts to 
the overall metabolic status and growth of the tumor. Subsequently, we focus on the 
importance of lactate uptake in cancer cells and more importantly the intricate changes to 
the tumors when the Warburg effect in CAFs is attenuated. These experiments ensure a 
clear approach in determining the contribution of metabolic activities in stromal fibroblasts to 
tumor growth.  
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Experiments and results 
To assess the functional contribution of αSMA+ myofibroblasts to the overall 
metabolic status and growth of the tumor, we used a reported transgenic mouse model to 
enable the specific ablation of αSMA+ myofibroblasts (Tse, 2011). In this transgenic mouse 
model, the αSMA promoter drives the expression of viral thymidine kinase (tk), such that 
ganciclovir (GCV) administration into αSMA-tk mice results in the signification depletion of 
αSMA+ cells (Figure 17A and B, reported by Tse, 2011). The loss of myofibroblasts 
significantly reduced tumor growth (Figure 17C and D, reported by Tse, 2011). The 
depletion of αSMA+ myofibroblasts also decreased the overall levels of glycolysis 
metabolites in the tumors including lactate, indicating that stromal fibroblasts are important 
contributors to the glycolysis activities of the tumor as a whole (Figure 18A and B). In 
addition, we separately assessed metabolites from the cancer cells isolated from αSMA-tk 
tumors. Surprisingly, cancer cells from αSMA-tk also showed a pattern of decreased 
metabolite accumulation similar to the overall tumors (Figure 18C and D). This experiment 
suggests that in association with diminished tumor growth the loss of stromal myofibroblasts 
can attenuate the Warburg effect within the cancer cells and the tumor as a whole. 
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Figrue 17. Ablation of αSMA+ myofibroblasts in αSMA-tk mice results in decreased tumor 
growth. 4T1 murine mammary epithelial cancer cells were implanted into the breast pads of 
either wildtype or αSMA-tk mice. (A) Staining of αSMA in tumors (αSMA in green, cell nuclei 
in blue), show the expected ablation effect following GCV treatment at day 12 post 
implantation. (B) Quantification of αSMA+ cells per visual field confirms significant ablation 
in stained tumors. Attenuated tumor volume (C) and weight (D) are observed in ganciclovir-
treated αSMA-tk mice (αSMA-tk+GCV) compared to control mice (WT+GCV). Data are 
represented as mean  SEM; *p<0.05. (A) and (B) are reproduced from doctoral 
dissertation of Tse (2011) with permission. 
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Figure 18. Ablation of αSMA+ myofibroblasts in αSMA-tk mice affects metabolism in tumors 
and cancer cells. Metabolomics was performed on whole tissues (A) or 4T1 cancer cells 
isolated from αSMA-tk+GCV and WT+GCV mice (C) from Figure 17. Heat maps (A) and (C) 
indicate differential metabolite accumulations in fibroblast-ablated tumors. Data for 
glycolysis were extracted; relative abundance was calculated as ratios between αSMA-
tk+GCV and WT+GCV for each metabolite (B and D). Analysis using Ingenuity Pathway 
Analysis software indicates significant different glycolysis not only between αSMA-tk+GCV 
and WT+GCV tumors but also between their respective isolated 4T1 cancer cells.  
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Figure 18 (continued) 
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The results of the αSMA-tk experiment suggest that the Warburg effect in stromal 
fibroblasts supports the Warburg effect in cancer cells. Lactate may be one of the 
mediators, being decreased in cancer cells of αSMA-tk tumors. To test this hypothesis, we 
targeted lactate production in fibroblasts and lactate uptake in cancer cells. Firstly, we 
knocked down Pdk in mouse embryonic fibroblasts (MEF) using shRNA prior to co-injection 
with 4T1 cancer cells into breast pads of mice. PDK inhibits entry of pyruvate into the TCA 
cycle. Consequently, the suppression of Pdk shifts glucose metabolism away from lactate 
production. Quantitative RT-PCR confirmed the significant downregulation of all Pdk genes 
in MEF+shPdk cells (Figure 19A). Lactate production was also significantly attenuated in 
these cells (Figure 19B), while no discernible differences in cell proliferation between Pdk 
silenced and control fibroblasts were observed. Co-injection of 4T1 cancer cells with Pdk-
knockdown fibroblasts resulted in decreased tumor growth (Figure 19C and D). Protein 
levels of GLUT1, HK2, PKM2, and LDHA were decreased in the knockdown tumors (Figure 
19E). When tumors were examined as a whole, metabolomic analysis demonstrated a 
decrease in most glycolysis metabolites including lactate (Figure 19F). Assessment of the 
metabolic profile of the cancer cells isolated from these tumors determined that Pdk 
suppression in fibroblasts also lead to decreased glycolysis metabolites in the cancer cells 
(Figure 19G). Although the stromal fibroblasts were manipulated to decrease lactate 
production, the affected cancer cells also shifted their glucose metabolism to less lactate 
production. 
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Figure 19. Shifting glucose metabolism away from lactate specifically in stromal fibroblasts 
impedes tumor growth and suppresses the Warburg effect in cancer cells. (A) Quantitative 
RT-PCR for Pdk expression in mouse embryonic fibroblasts expressing Pdk-targeting 
shRNA (MEF+shPdk) relative to control MEF. (B) Quantification of lactate levels in the 
culture media. (C) MEF+shPdk or control MEF was co-injected with 4T1 cancer cells and 
tumor volume was measured over 21 days. (D) Tumor weights at experimental endpoint. 
(E) Representative immunoblot of tumor lysates with antibodies against GLUT1, HK2, 
LDHA and PKM2. Metabolomics was performed on total tumor tissues (F) and tumor-
derived 4T1 cancer cells (G) from MEF+shPdk and control tumors. Data for glycolysis were 
extracted; relative abundance was calculated as ratios between MEF+shPdk and control 
MEF for each metabolite. Analysis using Ingenuity Pathway Analysis software indicates 
significant different glycolysis not only between MEF+shPdk and control tumors but also 
between their respective isolated 4T1 cancer cells. Data are represented as mean  SEM; 
*p<0.05. 
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Figure 19 (continued) 
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Figure 19 (continued) 
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4T1 cancer cells were subjected to Mct1 knockdown by shRNA prior to injection into 
breast pads of mice. Quantitative RT-PCR confirmed the downregulation of Mct1 in 4T1 
transfected with shMct1 (Figure 20A) and Mct1 knockdown resulted in significantly 
decreased tumor growth (Figure 20B and C). This finding is consistent with previous reports 
of decreased tumor growth observed in a lung mouse model and xenograft human 
colorectal cancer following treatments with small molecule inhibitor of MCT1 (Sonveaux et 
al., 2008).  
 
 
 
Figure 20. Inhibition of lactate uptake in cancer cells results in decreased tumor growth. 4T1 
cancer cells were transfected with either control shRNA (shCtrl) or Mct1 shRNA (shMct1) 
prior to orthotopic implantation in mice. (A) Quantitative RT-PCR for Mct1 expression in 
transfected cells. (B) Comparative tumor volumes were measured over 20 days. (C) Tumor 
weights at experimental endpoint. Data are represented as mean  SEM; *p<0.05. 
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Discussion 
 Our αSMA-tk experiment is the first evidence that CAFs contribute to the overall 
metabolism ongoing in the tumors. Furthermore, knockdown of Pdk in fibroblasts and Mct1 
in cancer cells supports the notion that the Warburg effect in CAFs assists tumor growth, 
likely through the provision of lactate.  
Combined, these data suggest that stromal fibroblasts contribute to the growth of 
tumors via direct metabolic support of the cancer cells. While others have demonstrated 
that the co-injection of highly glycolysis fibroblasts with cancer cells can increase tumor 
growth (Migneco et al., 2010), our studies specifically reveal that fibroblasts with increased 
lactate production will also increase lactate in cancer cells. Pdk suppression experiment 
suggests that the metabolic status of stromal fibroblasts is essential to tumor growth. 
Dichloroacetate (DCA), which inhibits the activity of PDKs and increases pyruvate utilization 
by the TCA cycle, has been explored as a possible cancer therapeutic in a few mouse 
studies (Bonnet et al., 2007; Sun et al., 2010). Preliminary assessment indicates that DCA 
exhibits anti-tumor effects in clinical trials (Michelakis et al., 2010). Our data suggests that 
the anti-tumor effects of DCA can also be due to its impact on stromal fibroblasts in the 
tumor.  
This study not only showcases the importance of metabolic functions of fibroblasts in 
tumor growth, but also calls for more emphasis in learning about glucose metabolism in 
tumor stromal constituents. Currently, there is no information on the metabolic states of 
pericytes, endothelial cells, epithelial and inflammatory cells in the context of tumors. These 
cells are active stromal components and known to contribute in different steps of tumor 
growth and progression. It is likely that they also contribute metabolically to the tumors, may 
be even compensate for the metabolic activities in cancer cells in the absence of fibroblasts. 
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These are important questions which regretfully cannot be covered under the scope of this 
dissertation.  
Recently, Fiaschi et al. (2012) have explored the metabolic reprogramming in 
fibroblasts exposed to prostate cancer cells. Although the cancer type is different than ours, 
the findings are similar. Exposed fibroblasts display Warburg phenotype, increased glucose 
uptake, and lactate production and secretion (Fiaschi et al., 2012). Pharmacologic inhibition 
of MCT1 in cancer cells strongly inhibits cell survival as well as prostate tumor growth 
(Fiaschi et al., 2012). This raises the question of whether metabolic reprogramming in 
fibroblasts is the same disregarding cancer type. Such information will help determine 
whether anti-metabolism is a relevant therapeutic option and further personalize cancer 
treatment for individual patients.  
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CHAPTER 5 
 
DISSERTATION SUMMARY  
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Cells normally use oxidative phosphorylation for efficient energy production and only 
shift to lactate production under anaerobic conditions. However, cancer cells have adapted 
to favor lactate production even at normal oxygen levels, exhibiting a metabolic shift known 
as the Warburg effect. While cancer cells rely on this altered metabolism for rapid 
proliferation and biosynthesis, the metabolic state of the other cellular constituents within 
the tumor remains mostly unknown.  In breast carcinomas, the stroma comprises of greater 
than 80% of the tumor mass with fibroblasts being the dominant stromal cell type. Thus, 
fibroblasts may be important contributors to glucose metabolism in the tumor. 
Through comparative studies between cancer-associated fibroblasts (CAFs) and 
normal mammary fibroblasts (NMFs) of human and mouse origins, we demonstrate that 
CAFs exhibit the Warburg effect with increased glycolysis and lactate production in aerobic 
condition with a trend of increased mitochondrial functions and defective antioxidant activity.  
We explore two different mechanisms that explain the Warburg effect in fibroblasts. 
Firstly, methylation studies suggest that enhanced glycolysis in CAFs may be due to 
epigenetic modifications of regulators of the pathway, fructose-bisphosphatase 1 and 
pyruvate kinase M2. Secondly, substantial exposure to hypoxia seems to induce prolonged 
expression of Hif1α via hypomethylation, driving overexpression of its transcriptional targets 
including glycolysis genes. 
To determine the functional contribution of Warburg effect in CAFs, we detail three in 
vivo studies. The first, fibroblast ablation in αSMA-tk mouse model, argues that stromal 
fibroblasts are actively contributing to the glucose metabolism ongoing inside the tumors. 
Knockdowns of pyruvate dehydrogenase kinase in fibroblasts and knockdown of lactate 
transporter in cancer cells indicate that not only metabolic status of CAFs affects tumor 
growth but also suggest that the Warburg effect in CAFs is possibly supporting it.  
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With all these results, we propose a model to describe the metabolic relationship 
between CAFs and cancer cells (Figure 21). In the growing tumor, stromal fibroblasts 
experience an environment full of growth factors, prompting them to proliferate; thus making 
their glucose metabolism changes to glycolysis and lactate production. As the tumor becomes 
a substantial mass, CAFs are exposed to direct contact with cancer cells, concentrated level 
of growth factors, and chronic hypoxia. This tumor progression induces fundamental shifts in 
expression of Hif1α and glycolysis genes such as Fbp1 and Pkm2. These changes allow 
CAFs to adopt the Warburg effect as a coping mechanism to the tumor microenvironment.  
 
Figure 21. Schematic of metabolic relationship between CAFs and cancer cells.  
 
We also highlight important unanswered questions and framing future directions for 
the field. Although the presented work uses fibroblasts from breast cancer, we hope to see its 
expansion to other cancers and relevant diseases. Strong understanding of glucose 
metabolism in diseased fibroblasts can greatly influence therapeutic strategy and ultimately 
improve patient care. 
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MATERIALS AND METHODS 
 
Cell lines 
 4T1 Balb/c mammary tumor epithelial cells (ATCC) and MEF (Millipore) were grown in 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal calf serum and 
penicillin/streptomycin (each 100U/ml). Human normal mammary fibroblasts and cancer-
associated fibroblasts were grown from breast biopsies obtained as part of an institutionally 
approved clinical study at Boston Brigham and Women’s Hospital in collaboration with Dr. 
Sughra Raza. Mouse normal mammary fibroblasts and cancer-associated fibroblasts were 
grown from tissues obtained from αSMA-RFP mice. Tissues were minced into <1mm3 
pieces and digested overnight with 300U/ml of Collagenase I. Collagenase mixture was 
replaced with RPMI-1640 media containing 20% fetal calf serum with 100U/ml 
penicillin/streptomycin and 250ng/ml amphotericin and fibroblasts were allowed to grow out 
of the tissue pieces. Grown cells underwent FACS to obtain pure αSMA-RFP+ populations.   
 
Transgenic mice 
 αSMA-RFP and αSMA-tk mice were generated by our laboratory using an extended 
αSMA promoter containing approximately 2.4kb of the αSMA promoter plus exon 1, intron 
1, and part of exon 2 (altogether 5.2kb) amplified with the following primers: 5’ CAATGC 
ATGCTGTACAAACATCAGG 3’ (Forward); 5’ AGCTGGAGCAGCGTCTCAGGGT 
TCTGC 3’ (Reverse). For the αSMA-RFP mice, the extended αSMA promoter was cloned 
into the pDsRed-Express-1 vector (Clontech) using EcoRI and SalI restriction sites, and the 
whole αSMA-RFP construct was released from the vector using EcoRI and DrdI before 
purification and injection into fertilized eggs. For the αSMA-tk mice, a truncated version of 
the herpes simplex 1 virus thymidine kinase (HSV1-tk) gene with 3’ UTR was amplified from 
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plasmid fsp1-TK using the following primers: 5’ ATGCCCACGCTACTGCGGG 3’ (Forward); 
5’ GTGGATAACCGTATTACCGCC 3’ (Reverse). The extended αSMA promoter was cloned 
into the pCR2.1-TOPO vector (Invitrogen) using EcoRI and NotI restriction sites, then this 
αSMA promoter-TOPO construct and the tk fragment were digested and ligated together. 
The whole αSMA-tk construct was released from the vector using EcoRI and XbaI then 
purified and injected into fertilized eggs. All transgenic mice were created in the Brigham 
and Women’s Hospital Transgenic Core Facility on a FVB background and backcrossed 
more than 7 generations to a BALB/c background for experiments. Mice were generated by 
Dr. Yingqi Teng and Dr. Joyce O’Connell (BIDMC and Harvard Medical School, Boston).  
 
Generation of knockdowns 
 MEF clones containing knockdown of Pdk were made following the Addgene protocol 
using pLKO.1 – TRC cloning vector with help from Dr. Valerie LeBleu. shRNA oligos were 5’ 
CCGGGAACTCCGACCAGAAGCCAAGAATTCTCGAGAATTCTTGGCTTCTGGTCGGAGT
TCTTTTTG 3’ (Forward) and 5’ AATTCAAAAAGAACTCCGACCAGAAGCCAAGAATTCT 
CGAGAATTCTTGGCTTCTGGTCGGAGTTC 3’ (Reverse). Target sequence was 5’ 
GAACTCCGACCAGAAGCCAAGAATT 3’. Control scrambled shRNA oligos were 5’ 
CCGGGAACACGTCAGACCAGGATCACATACTCGAGTATGTGATCCTGGTCTGACGTGT
TCTTTTTG 3’ (Forward) and 5’ AATTCAAAAAGAACACGTCAGACCAGGATCACATACT 
CGAGTATGTGATCCTGGTCTGACGTGTTC 3’ (Reverse) with target sequence being  
5’ GAACACGTCAGACCAGGATCACATA 3’. 
 4T1 clones containing knockdown of Mct1 were made by transfecting shRNA 
(Origene) in Lipofectamine lipid carrier (Invitrogen) using standard transfection protocol. 
Clone selection with 4ug/ml puromycin was done prior to clone picking and verification of 
gene knockdown was confirmed with qRT-PCR. Scrambled shRNA (Origene) was control.  
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Cancer cell implantation 
 Female BALB/c mice were used for orthotopic mammary fat pad injection of 4T1 
mouse mammary carcinoma cells. 1x10
6
 tumor cells were injected into the mammary fat 
pad in 20μl of PBS (with help from Dr. Joyce O’Connell); mice were sacrificed 24 days post 
cancer cell implantation. αSMA-tk mice experiment was from Tse (2011). Briefly, mice 
received daily intraperitoneal injections with 50mg/kg of ganciclovir starting 12 days post 
cancer cell implantation. MEF were mixed with 4T1 cells at a 2:1 ratio for orthotopic 
implantation into the mammary fat pad, and mice were sacrificed 21 days post cancer cell 
implantation. Tumor volumes were measured using Vernier calipers and volumes were 
calculated using a standard formula (length x width
2
 x 0.52). Age-matched mice were used 
for all studies. Mouse studies followed the Institutional Animal Care and Use Guidelines at 
the BIDMC. 
 
Fluorescence-activated cell sorting  
 Fluorescence-activated cell sorting (FACS) was performed on single cell suspensions. 
Tissues were chopped finely then incubated in 1mg/ml collagenase/dispase solution 
(Roche) for 1 hour in a 37°C shaker. The resulting suspension was filtered through a 40μm 
cell strainer, treated with ACK lysis buffer for removal of red blood cells and resuspended in 
PBS sorting solution of 2% FBS in plus propidium iodide. Cultured cells were trypsinized 
and pelleted before filtering and resuspension in sorting solution and sorted at Joslin Flow 
Cytometry Core Facility.  
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Microarray 
 For tumors and human fibroblasts, RNAs were extracted with TRIzol (Invitrogen) per 
manufacturer’s instructions. For mouse fibroblasts, αSMA-RFP+ stromal cells were isolated 
by fluorescence-activated cell sorting (FACS) from normal breast tissues and tumors. RNA 
was extracted immediately using the Qiagen RNeasy Plus Micro Kit per manufacturer’s 
instructions, then amplified with the NuGen WT-Ovation Pico Kit (done by Dr. Joyce 
O’Connell). Microarray hybridization to the Human HT-12 Expression BeadChip or the 
Mouse Ref-8 Expression BeadChip (Illumina) was performed by the Molecular Genetics 
Core Facility at Children’s Hospital Boston. The Ingenuity Pathways Analysis software was 
used for comparative gene expression with help from Dr. Joyce O’Connell.  
 
Quantitative real time PCR 
 Primers were used with SYBR Green PCR Master Mix in a 7300 Sequence Detector 
System (Applied Biosystems) and measurements were standardized to expression of the 
housekeeping genes, either acidic ribosomal phosphoprotein PO (ARP/ 36B4) or β-actin. 
Fold-change in gene expression was determined using the ∆∆Ct method. For primer 
sequences, see below.  
 
Table 3. qRT-PCR primer sequences.  
Gene Species Primer sequences 
Glut1 
M. 
Musculus 
F 5’ AGTGTATCCTGTTGCCCTTCT 3’ 
R 5’ CATCGGCTGTCCCTCGAAGC 3’ 
H. Sapien 
F 5' AAGGTGATCGAGGAGTTCTACA 3' 
R 5' ATGCCCCCAACAGAAAAGATG 3' 
Hk2 
M. 
Musculus 
F 5’ GGAACCGCCTAGAAATCTCC 3’ 
R 5’ GGAGCTCAACCAAAACCAAG 3’ 
H. Sapien 
F 5' TTTGACCACATTGCCGAATGC 3' 
R 5' GGTCCATGAGACCAGGAAACT 3' 
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Table 3 (continued) 
Gene Species Primer sequences 
LdhA 
M. 
Musculus 
F 5’ TGGAGTGGAATGAATGTTGC 3’ 
R 5’ ATAGCCCAGGATGTGTAGCC 3’ 
H. Sapien 
F 5' CAGCCCGAACTGCAAGTTG 3' 
R 5' CCCCCATCAGGTAACGGAATC 3' 
Pkm2 
M. 
Musculus 
F 5’ GCCGCCTGGACATTGACTC 3’  
R 5’ CCATGAGAGAAATTCAGCCGAG 3’  
H. Sapien 
F 5’ ATGTCGAAGCCCGATAGTGAA 3’  
R 5’ TGGGTGGTGAATCAATGTCCA 3’  
Pfkl 
M. 
Musculus 
F 5’ CCCTGACAGCAGCATTCATA 3’  
R 5’ CTACCGTGGACCTGGAGAAA 3’  
H. Sapien 
F 5’ GCTGGGCGGCACTATCATT 3’  
R 5’ TCAGGTGCGAGTAGGTCCG 3’  
Mct4 
M. 
Musculus 
F 5' GGGGCCTACTGCTCAACTG 3'  
R 5' CGGTCTCGGAAGACACTCAG 3'  
H. Sapien 
F 5' TGACTGGACAGGTATCCTTGAG 3'  
R 5' AGTAGTGGAAATGTGGTGGCTA 3' 
Mct1 
M. 
Musculus 
F 5' TGTTAGTCGGAGCCTTCATTTC 3' 
R 5' CACTGGTCGTTGCACTGAATA 3' 
Hif1α H. Sapien 
F 5' CTGCCACCACTGATGAATTA 3'  
F 5' GTATGTGGGTAGGAGATGGA 3'  
Pdk1 
M. 
Musculus 
F 5’ TTACTCAGTGGAACACCGCC 3’  
R 5’ GTTTATCCCCCGATTCAGGT 3’  
Pdk2 
M. 
Musculus 
F 5’ AGGGGCACCCAAGTACATC 3’  
R 5’ TGCCGGAGGAAAGTGAATGAC 3’  
Pdk3 
M. 
Musculus 
F 5’ TCCTGGACTTCGGAAGGGATA 3’  
R 5’ GAAGGGCGGTTCAACAAGTTA 3’  
Pdk4 
M. 
Musculus 
F 5’ CTTCTGGGCTCTTCTCATGG 3’ 
R 5’ GATTGACATCCTGCCTGACC 3’ 
Fbp1 H. Sapien 
F 5' CTACGCCAGGGACTTTGACC 3'  
R 5' GGCCCCATAAGGAGCTGAAT 3'  
Arp/36b4 
M. 
Musculus 
F 5’ GGAGCCAGCGAGGCCACACTGCTG 3’ 
R 5’ CTGGCCACGTTGCGGACACCCTCC 3’ 
β-actin H. Sapien 
F 5' CATGTACGTTGCTATCCAGGC 3' 
R 5' CTCCTTAATGTCACGCACGAT 3' 
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Metabolomics 
 Metabolomics was done with targeted mass spectrometry through collaboration with 
Dr. John Asara (BIDMC, Boston). For cultured cells, 4ml of 80% LC-MS grade methanol 
was added to each 10cm dish and incubated at -80°C for 15 minutes. Cells were scraped 
and collected from plate to be centrifuged at full speed for 5 minutes at 4°C to pellet cell 
debris and proteins. Supernatants were saved. Pellets were resuspended in 500μl 80% 
methanol by vortexing and subsequently centrifuged as before. Supernatant was collected 
and pellet resuspension was repeated. The three extracted supernatants were pooled for 
drying step. For tissues, 400ml of 80% LC-MS grade methanol was added per 1-2mg 
weight and homogenized for 30 seconds at -80°C then centrifuged at 14,000rpm for 10 
minutes at 4°C. Supernatants were collected and the steps from the beginning were 
repeated twice. Supernatants from all three extractions were pooled and centrifuged a final 
time at 14,000rpm for 10 minutes at 4°C. For FACS cells, 400-500μl 80% methanol was 
used per sample and the above described subsequent steps were followed. Metabolite 
supernatants were dried by SpeedVac. Samples were re-suspended using 20μL HPLC 
grade water for mass spectrometry. A total of 299 endogenous water soluble metabolites 
including some in both positive and negative ion mode were analyzed by a 5500 QTRAP 
triple quadrupole mass spectrometer (AB/Sciex) coupled to a Prominence UFLC HPLC 
system (Shimadzu) via selected reaction monitoring (SRM). Metabolomics data analysis 
was done using Metaboanalyst software (www.metaboanalsyst.ca) with the following 
settings: 1) automatic removal of variables with >50% missing values, 2) calculation of the 
remaining missing values as half of the minimum positive value in the original data, and 3) 
autoscaling for column-wise normalization. Relative metabolite abundance for each 
metabolite was calculated and graphed in log2 scale (done with help from Dr. Joyce 
O’Connell).  
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Quantification of lactate 
 L-Lactate Assay Kit was purchased from Eton Bioscience Inc. and used per 
manufacturer’s instructions. Cells were plated at the same number and volume. Culture 
mediums were collected 72 hours later and were diluted 1:10 with ddH2O prior to adding 
assay solution. Concentrations of lactate in samples were determined with the standard 
curve. Cell numbers counted at the time of medium harvest were used for normalization. 
Relative ratio of CAFs to NMFs was calculated and graphed.  
 
Assessments of mitochondrial functions 
 Cells were plated in triplicate at 4x10^4 cells/well into XF24 plate for 24 hours prior to 
assay with XF Cell Mito Stress Kit using the XF24 Analyzer plate reader (in collaboration 
with Karina Gonzales and Dr. Marcia Haigis, Harvard Medical School, Boston). Rotenone 
was used at 1uM final concentration to obtain mitochondrial-specific OCR. All products were 
obtained from Seahorse Bioscience. Gathered OCR, PPR and ECAR data were normalized 
to cell number (crystal violet) and relative rates were calculated for comparison. Activities of 
complexes I, II and IV of the electron transport chain were determined by level of NADH, 
fumarate/succinate and ATP/ADP ratios respectively (quantification done by metabolomics). 
Relative activities were calculated for comparison. mtDNA contents were measured on 
whole cell DNA extracts by qRT-PCR (done by Dr. Joyce O’Connell) with the following  
sequences: 
Cyba         F 5’  CCCAGTGGTACTTTGGTGCC 3’ 
                 R 5’ GCGGTCATGTACTTCTGTCCC 3’ 
β-Globin    F 5’ AGGAGAAGTCTGCCGTTACTG 3’ 
                  R 5’ CCGAGCACTTTCTTGCCATGA 3’  
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Immunoblotting 
 Homogenized tissues and cells were lysed with RIPA buffer using standard protocol. 
Protein concentrations were determined by BCA Protein Assay (Thermo Scientific) with a 
microplate reader at 562nm. Lysates were run on 10% polyacrylamide gels and proteins 
transferred onto PVDF membranes overnight. Membranes were blocked with 5% milk in 
TBS-T. Antibodies detecting GLUT1 (Abcam), HK2 (Cell Signaling), LDHA (Cell Signaling), 
β-ACTIN (Sigma), MCT1 (Santa Cruz), MCT4 (Santa Cruz), HIF1α (Novus Biologicals), β-
TUBULIN (Abcam) and PKM2 (generously provided by Dr. Matthew Vander Heiden) were 
used at recommended dilutions for either 4 hours at room temperature or overnight at 4C 
on shaker. Appropriate HRP-conjugated secondary antibodies (Sigma) were used at 
1:10,000 dilution for one hour at room temperature on shaker. Membranes were exposed to 
ECL solution (Thermo Scientific) prior to film exposure.  
 
Methylation studies 
 Genomic DNAs were isolated using high salt precipitation protocol and subsequently 
purified. Next, high throughput methylation specific oligonucleotide microarray was 
performed (~27,500 CpG islands with ~485,000 probes) in collaboration with Dr. Manuel 
Esteller (IDIBELL, Spain). Percent methylation data and heat map were generated by Javier 
Carmona Sanz (IDIBELL, Spain) and differential % of methylation for each probe was 
calculated to compare CAF to NMF.  
 Methylated DNA immunoprecipitation followed by SYBR-based real time PCR (in 
collaboration with Dr. Desiree Tampe and Dr. Michael Zeisberg (University Hospital 
Goettingen, Germany) was completed for Fbp1, Pkm2 and Hif1α. PCR band intensities 
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were quantified and average %MeDIP/input DNA were calculated. In addition, bisulfite 
sequencing of Fbp1 was also performed (IDIBELL, Spain).   
Primer sequences 
Fbp1     F 5’ CGAGCGCTGCGGACACTCGGG 3’  
             R 5’ CGCACCGCCGAAGAGATGGC 3’  
Pkm2    F 5’ CTACTCTGAGGCATTCGCTCTGC 3’ 
             R 5’ CCGGGTGTCTGCTCTGGCGCAC 3’ 
Hif1α     F 5’ GGAGAAAGAGAGCAGGAGCATTAC 3’  
              R 5’ GCTCGTCTGTGTTTAGCGGCGGAGG 3’  
 
Statistical analysis 
 For comparison between two groups, a two-tailed t-test was performed. P-value <0.05 
constitutes statistical significance. 
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